Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. (Q34667915)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

4 January 2020

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Richard Cohn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Vowels MR

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Johnston K

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Russell SJ

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Neville KA

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Carroll S

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Marshall GM

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

27 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

741-746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth after transplantation for leukemia or aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Long-term complications in survivors of advanced stage neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Neuropsychological resiliency after treatment for advanced stage neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Endocrine late effects from multi-modality treatment of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Osteochondroma after total body irradiation: an age-related complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Peripheral blood stem cell autografts for the treatment of children over 1 year old with stage IV neuroblastoma: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Development of normalized curves for the international growth reference: historical and technical considerations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Endocrine deficit after fractionated total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705809

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705809

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724446%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 January 2020

1023536051

0 references

1 reference